| Literature DB >> 21711705 |
Tokuyuki Yoshida1, Yasuo Yoshioka, Maho Fujimura, Kohei Yamashita, Kazuma Higashisaka, Yuki Morishita, Hiroyuki Kayamuro, Hiromi Nabeshi, Kazuya Nagano, Yasuhiro Abe, Haruhiko Kamada, Shin-Ichi Tsunoda, Norio Itoh, Tomoaki Yoshikawa, Yasuo Tsutsumi.
Abstract
With the increase in use of nanomaterials, there is growing concern regarding their potential health risks. However, few studies have assessed the role of the different physical characteristics of nanomaterials in allergic responses. Here, we examined whether intranasally administered silica particles of various sizes have the capacity to promote allergic immune responses in mice. We used nanosilica particles with diameters of 30 or 70 nm (nSP30 or nSP70, respectively), and conventional micro-sized silica particles with diameters of 300 or 1000 nm (nSP300 or mSP1000, respectively). Mice were intranasally exposed to ovalbumin (OVA) plus each silica particle, and the levels of OVA-specific antibodies (Abs) in the plasma were determined. Intranasal exposure to OVA plus smaller nanosilica particles tended to induce a higher level of OVA-specific immunoglobulin (Ig) E, IgG and IgG1 Abs than did exposure to OVA plus larger silica particles. Splenocytes from mice exposed to OVA plus nSP30 secreted higher levels of Th2-type cytokines than mice exposed to OVA alone. Taken together, these results indicate that nanosilica particles can induce allergen-specific Th2-type allergic immune responses in vivo. This study provides the foundations for the establishment of safe and effective forms of nanosilica particles.Entities:
Year: 2011 PMID: 21711705 PMCID: PMC3211251 DOI: 10.1186/1556-276X-6-195
Source DB: PubMed Journal: Nanoscale Res Lett ISSN: 1556-276X Impact factor: 4.703
Figure 1Plasma OVA-specific IgE Ab responses after intranasal exposure to OVA plus silica particles. (a) BALB/c mice were intranasally exposed to PBS (vehicle control), OVA alone or OVA plus silica particles (250 μg/mouse) on days 0, 1, and 2. (b) BALB/c mice were intranasally exposed to PBS (vehicle control), OVA alone or OVA plus the designated dose of nSP30 or nSP70 on days 0, 1, and 2. Plasma was collected on day 21 and analyzed by ELISA to assess (a) the relationship between silica particle size and OVA-specific IgE Ab responses and (b) the dose-response effect of nSP30 and nSP70 on OVA-specific IgE Ab levels. N.D., not detected. Data are presented as mean ± SEM (n = 8 to 13; *P < 0.05 vs OVA alone).
Figure 2Plasma OVA-specific IgG and subclass IgG1 Ab response after intranasal exposure to OVA plus silica particles. BALB/c mice were intranasally exposed to PBS (vehicle control), OVA alone or OVA plus silica particles (250 μg/mouse) on days 0, 1, and 2. Plasma was collected on day 21 and analyzed by ELISA to detect the level of (a) OVA-specific IgG and (b) OVA-specific IgG1 Ab responses. Data represent mean absorbance at a wavelength of 450 nm (reference wavelength, 655 nm). N.D., not detected. Data are presented as mean ± SEM (n = 5 to 8); *P < 0.05, **P < 0.01 vs OVA alone; P < 0.01 vs PBS).
Figure 3Cytokine responses induced after intranasal exposure to OVA plus silica particles. BALB/c mice were intranasally exposed to PBS (vehicle control), OVA alone or OVA plus silica particles (250 μg/mouse) on days 0, 1, and 2. On day 21, splenocytes from each group were prepared and cultured with 1 mg/mL OVA. Culture supernatants were harvested after 3 days of incubation, and the level of OVA-induced IL-4 (A) and IL-5 (B) produced and released into the culture supernatant was analyzed using the Bio-Plex Multiplex Cytokine Assay. Data are presented as mean ± SEM (n = 3; *P < 0.05 vs OVA alone; P < 0.05 vs PBS).